GALT
Galectin Therapeutics Inc

10,053
Loading...
Loading...
News
all
press releases
Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know
Does Galectin Therapeutics Inc. (GALT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Top 5 Biotech Stocks Dominating Retail Investor Conversations In 2024
From Tonix Pharmaceuticals’ progress on fibromyalgia treatments to Nvidia-backed Recursion Pharmaceuticals, these stocks sparked significant message volume growth on Stocktwits.
Stocktwits·9mo ago
News Placeholder
Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
read more...
Benzinga·1y ago
News Placeholder
FY2025 EPS Estimates for Galectin Therapeutics Inc. Lowered by Analyst (NASDAQ:GALT)
Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Research analysts at HC Wainwright lowered their FY2025 EPS estimates for shares of Galectin Therapeutics in a report released on Monday...
Zolmax·1y ago
News Placeholder
Retirement Guys Formula LLC Boosts Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT)
Retirement Guys Formula LLC grew its stake in shares of Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 87.0% during the fourth quarter, according to the company in its most recent 13F...
Ticker Report·1y ago
News Placeholder
Galectin Therapeutics (NASDAQ:GALT) Rating Reiterated by HC Wainwright
Galectin Therapeutics (NASDAQ:GALT - Get Free Report)s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They...
Ticker Report·1y ago
News Placeholder
Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments
Comparing GALT's Performance Against Analyst Estimates and Exploring Future ProspectsRelated Stocks: GALT...
GuruFocus·1y ago
News Placeholder
Galectin Therapeutics GAAP EPS of -$0.74
Galectin Therapeutics GAAP EPS of -$0.74...
SeekingAlpha.com: All News·1y ago
News Placeholder
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results...
Globe Newswire·1y ago
News Placeholder
Galectin Therapeutics (NASDAQ:GALT) Lowered to Sell at StockNews.com
StockNews.com downgraded shares of Galectin Therapeutics (NASDAQ:GALT Free Report) from a hold rating to a sell rating in a research report report published on Monday. Galectin Therapeutics...
Ticker Report·1y ago

Latest GALT News

View

Advertisement. Remove ads.

Advertisement. Remove ads.